Production (Stage)
United Therapeutics Corporation
UTHR
$307.65
-$1.07-0.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.21B | 1.20B | 1.11B | 1.07B | 1.05B |
| Total Depreciation and Amortization | 77.30M | 72.50M | 66.50M | 60.70M | 54.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 145.80M | 119.70M | 106.90M | 90.20M | 59.50M |
| Change in Net Operating Assets | -22.00M | -60.20M | -147.70M | -114.70M | -185.20M |
| Cash from Operations | 1.41B | 1.33B | 1.14B | 1.11B | 979.70M |
| Capital Expenditure | -283.20M | -246.50M | -238.50M | -227.70M | -227.30M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -89.20M | -89.20M | -89.20M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -199.60M | 663.70M | 910.20M | 700.90M | 553.30M |
| Cash from Investing | -482.80M | 417.20M | 582.50M | 384.00M | 236.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -400.00M | -400.00M | -400.00M | -300.00M | -200.00M |
| Issuance of Common Stock | 135.50M | 160.10M | 141.80M | 113.30M | 85.90M |
| Repurchase of Common Stock | -16.10M | -1.01B | -1.01B | -1.01B | -1.01B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -2.70M | -2.70M | -2.70M | -2.70M |
| Cash from Financing | -280.60M | -1.25B | -1.27B | -1.20B | -1.13B |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 648.40M | 489.50M | 446.20M | 288.40M | 88.00M |